Skip to main content
X4 Pharmaceuticals, Inc logo

X4 Pharmaceuticals, Inc — Investor Relations & Filings

Ticker · XFOR ISIN · US0428731097 LEI · 549300R0UFVPXWP86U94 US Manufacturing
Open in API
Filings indexed 784 across all filing types
Latest filing 2020-03-03 Director's Dealing
Country US United States of America
Listing US XFOR

About X4 Pharmaceuticals, Inc

https://www.x4pharma.com/

X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases of the immune system. The company focuses on diseases resulting from the dysfunction of the CXCR4 pathway, a key signaling pathway for immune cell trafficking. Its lead product, XOLREMDI™ (mavorixafor), is an oral, selective antagonist of the CXCR4 receptor. It is approved for use in patients aged 12 and older with WHIM syndrome (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) to increase the number of circulating neutrophils and lymphocytes. The company's pipeline includes further investigation of mavorixafor for other chronic neutropenic disorders.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2020-03-03 English
AMENDMENT NO. 1 TO THE SCHEDULE 13G
Major Shareholding Notification
2020-02-14 English
SCHEDULE 13G
Major Shareholding Notification
2020-02-14 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-02-14 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-02-14 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The content focuses on amendments to employment arrangements of senior executives, specifically changes to severance and change of control provisions for the CEO and CFO. This relates to management changes or compensation arrangements but does not announce a change in board membership or new appointments. It is not a full annual or quarterly report, nor an earnings release or proxy statement. The document is not a certification or a report publication announcement. The primary subject is amendments to executive employment agreements, which falls under Board/Management Information category as it concerns management compensation and arrangements. Therefore, the appropriate classification is MANG (Board/Management Information). The document length and detail support a high confidence in this classification.
2020-02-13 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.